Integrating risk profiles for disease progression in the treatment choice for patients with lower urinary tract symptoms/benign prostatic hyperplasia: A combined analysis of external evidence and clinical expertise

Prostate Cancer and Prostatic Diseases

Volumn 8, Issue 4, 2005, Pages 369-374

  Speakman, M ^a   Batista, J ^b   Berges, R ^c   Chartier Kastler, E ^d   Conti, G ^e   Desgrandchamps, F ^f   Dreikorn, K ^g   Lowe, F ^h   O'Leary, M ⁱ   Perez, M ^j   Trachtenberg, J ^k   Tubaro, A ^l   Meesen, B ^m   Smets, L ^m   Stoevelaar, H ⁿ  

^a TAUNTON AND SOMERSET HOSPITAL   (United Kingdom)

^b CENTRO MÉDICO TEKNON   (Spain)

^c PAN Klinik am Neumarkt   (Germany)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e SANT ANNA HOSPITAL   (Italy)

^f SAINT LOUIS HOSPITAL   (France)

^g Zentralkrankenhaus St Juergenstrasse   (Germany)

^h ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

ⁱ BRIGHAM AND WOMEN S HOSPITAL   (United States)

^j Department of Vascular Surgery   (Brazil)

^k PRINCESS MARGARET HOSPITAL   (Canada)

^l SAPIENZA UNIVERSITY OF ROME   (Italy)

^m Ismar Healthcare ^*  (Belgium)

ⁿ ERASMUS MEDICAL CENTER   (Netherlands)

more..

Author keywords

Benign prostatic hyperplasia; Evidence based medicine; Lower urinary tract symptoms; RAND appropriateness method; Risk factors

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; PLANT EXTRACT; STEROID 5ALPHA REDUCTASE INHIBITOR;

ARTICLE; CLINICAL TRIAL; DISEASE COURSE; DISEASE SEVERITY; DRUG CHOICE; EVIDENCE BASED MEDICINE; HUMAN; MALE; MEDICAL EXPERT; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; PROSTATE SURGERY; RISK FACTOR; URETHRA DISEASE; URINE FLOW RATE;

DISEASE PROGRESSION; HUMANS; MALE; PROSTATIC HYPERPLASIA; RISK FACTORS; UROLOGIC DISEASES;

EID: 30544436072     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/sj.pcan.4500827     Document Type: Article

References (22)

1. Lee AJ et al. The natural history of untreated lower urinary tract symptoms in middle-aged and elderly men over a period of five years. Eur Urol 1998; 34: 325-332.
2. Dobrovits M et al. A longitudinal prospective study of men with mild symptoms of BOO treated with watchful waiting over 4 years. Eur Urol Suppl 2003; 2: 26 (Abstract 96).
3. Tubaro A, Miano L. Managing the consequences of obstruction. Eur Urol Suppl 2002; 1: 21-27.
4. McConnell JD et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003; 349: 2387-2398.
5. Jacobsen SJ et al. Natural history of prostatism: Risk factors for acute urinary retention. J Urol 1997; 158: 481-487.
6. McConnell JD et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med 1998; 338: 557-563.
7. Roehrborn CG et al. Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. Urology 1999; 53: 473-480.
8. McConnell JD et al. Baseline measures predict the risk of benign prostatic hyperplasia clinical progression in placebo-treated patients. J Urol 2003; 169 (Suppl): 332 (Abstract 1287).
9. Roehrborn CG, Boyle P Nickel JC. PSA is a significant predictor of objective parameters in men at risk of BPH progression. J Urol 2003; 169 (Suppl): 364-365, (Abstract 1362).
10. Jimenez-Cruz F. Identifying patients with lower urinary tract symptoms/ benign prostatic hyperplasia (LUTS/BPH) at risk for progression. Eur Urol Suppl 2003; 2: 6-12.
11. Lowe FC et al. Risk factors for disease progression in patients with lower urinary tract symptoms/benign prostatic hyperplasia (LUTS/BPH): A systematic analysis of expert opinion. Prostate Cancer Prostatic Dis 2005; 8: 206-209.
12. Brook RH et al. A method for the detailed assessment of the appropriateness of medical technologies. Int J Technol Assess Health Care 1986; 2: 53-63.
13. Shekelle P. The appropriateness method. Med Decis Making 2004; 24: 228-231.
14. Meesen B. LUTS/BPH Progression. A Literature Review on Risk Factors for Progression and Impact of Medical Therapy on Progression. ISMAR Healthcare: Lier, Belgium, 2003.
15. O'Leary M et al. Treatment choice in relation to the patient's risk profile in lower urinary tract symptoms/benign prostatic hyperplasia: A systematic analysis of expert opinion. J Urol 2004; 171 (4 Suppl): 357 (Abstract 1357).
16. Fitch K et al. The RAND/UCLA Appropriateness Method. User's Manual. RAND: Santa Monica, 2001.
17. Roehrborn CG, Boyle P, Gould AL, Waldstreicher J. Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia. Urology 1999; 53: 581-589.
18. Vaughan ED. Medical management of benign prostatic hyperplasia - are two drugs better than one? N Engl J Med 2003; 349: 2449-2451.
19. AUA Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations. J Urol 2003; 170: 530-547.
20. Stoevelaar HJ, McDonnell J, Van de Beek C, Casparie AF. Appropriate treatment of benign prostatic hyperplasia; refining the indications for treatment by systematic analysis of expert opinion. Ned Tijdschr Geneeskd 1999; 143: 2425-2429.
21. Stoevelaar HJ et al. Lower urinary tract symptoms suggestive of benign prostatic obstruction: How can clinical expertise contribute to rational management? Eur Urol 2001; 39 (Suppl 3): 13-19.
22. McDonnell J, Stoevelaar HJ, Bosch JL, Kahan JP. The appropriateness of treatment of benign prostatic hyperplasia: A comparison of Dutch and multinational criteria. Health Policy 2001; 57: 45-56.